Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases.

Jason R Ni, Matthew Quirk, Bartosz Chmielowski, Siddharth A Padia

Abstract read

In one paragraph

Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jason R NiDivision of Interventional Radiology, Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, 757 Westwood Plaza, Suite 2125, Los Angeles, CA, 90095, USA.

Matthew QuirkDivision of Interventional Radiology, Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, 757 Westwood Plaza, Suite 2125, Los Angeles, CA, 90095, USA.

Bartosz ChmielowskiDivision of Hematology-Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

Siddharth A PadiaDivision of Interventional Radiology, Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, 757 Westwood Plaza, Suite 2125, Los Angeles, CA, 90095, USA. spadia@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-3975-7479

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAssessing the safety and efficacy of Yttrium-90 ( MATERIALS AND

methodsAn IRB-approved retrospective study of patients with liver metastases from uveal melanoma treated by radioembolization from 2017 to 2023 was performed. 25 patients (9 males, 16 females) with a median age at metastatic diagnosis of 62 years (range 30-78) underwent a total of 52 glass radioembolization procedures. Date of diagnosis and metastasis, tumor characteristics, concomitant therapies, treatment dosage, treatment related toxicities, survival, and imaging response were collected and reviewed. Imaging response was based on RECIST criteria as well as complete or partial radiographic response of the index tumor.

resultsMean index tumor size was 4.1 ± 1.0 cm (range 0.9-20). Complete radiographic response (n = 32) or partial response (n = 17) was achieved in 49/52 (94%) treatments. Segmental radioembolization showed higher rates of complete radiographic response compared to lobar radioembolization (78% vs. 35%, p < 0.05). Index tumor size was an independent factor in achieving optimal response rates for radiation segmentectomy (p < 0.05). Overall RECIST disease control rate was 84% (21/25). Median progression free survival and median overall survival from index treatment was 8.0 months (range 0.7-49.0) and 20.3 months (range 1.6-53.1), respectively. One year survival was 76% (19/25). Twelve mild Grade 1a clinical toxicities were reported (48%).

conclusionThis study supports

Indexed as

Liver NeoplasmsMelanomaRadioembolization, TherapeuticUveal NeoplasmsYttrium RadioisotopesAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeUveal MelanomaYttrium-90Yttrium RadioisotopesHepatic metastasesSelective internal radiation therapyUveal melanomaYttrium-90 radioembolization

Identifiers

PMID41714380

DOI10.1007/s00270-026-04373-y

PMCPMC13156169

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.